Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)/ Covid-19
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Anakinra (Primary) ; Apremilast (Primary) ; Eritoran (Primary) ; Hydroxychloroquine (Primary) ; Interferon beta-1a (Primary) ; Lopinavir/ritonavir (Primary) ; Mercaptamine (Primary) ; Sarilumab (Primary) ; Tocilizumab (Primary) ; TRV 027 (Primary) ; Amoxicillin/clavulanic acid; Ascorbic acid; Aspirin; Azithromycin; Azithromycin; Baloxavir-marboxil; Baricitinib; Ceftaroline fosamil; Ceftriaxone; Clarithromycin; Clarithromycin; Clopidogrel; Convalescent anti-SARS-CoV-2 plasma; Dalteparin sodium; Dalteparin sodium; Dexamethasone; Dexamethasone; Erythromycin; Heparin; Hydrocortisone; Interferon beta-1; Levofloxacin; Lopinavir; Lopinavir; Low molecular weight heparins; Macrolides; Moxifloxacin; Oseltamivir; Piperacillin/tazobactam; Plasma; Prasugrel; Ritonavir; Roxithromycin; Simvastatin; Ticagrelor; Vitamins
- Indications Community-acquired pneumonia; COVID 2019 infections; COVID-19 pneumonia; Influenza virus infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms AD-SCAP; REMAP-CAP; REMAP-COVID
- 25 Oct 2023 Results published in the New England Journal of Medicine
- 12 Sep 2023 Planned number of patients changed from 10000 to 20000.
- 01 Jun 2023 Planned End Date changed from 1 Dec 2025 to 1 Feb 2028.
Most Recent Events
Trial Overview
Outcome
Purpose
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Comments
According to a Global Coalition for Adaptive Research media release, company has ended the evaluation of eritoran in the REMAP-COVID study. The decision to terminate the evaluation was due to changes in the COVID-19 landscape.
As per result published in the JAMA: the Journal of the American Medical Association, enrollment is discontinued after the prespecified criterion for futility met for the pooled antiplatelet group compared with control.
Primary Endpoints
organ support–free days
(days alive and free of ICU-based respiratory or cardiovascular support) within 21 days
respiratory and cardiovascular organ support–free days, on an ordinal scale combining in-hospital death (assigned a value of −1) and days free of organ support to day [1]
All-cause mortality
time_frame: Day 90
Days alive and not receiving organ support in ICU
description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
time_frame: Day 21
The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days.
Timepoint: 90 Days from the date of enrolment.
For the REMAP-COVID substudy
The organ failure free days over a 21 day observational period.
The primary outcome for all domains will be the occurrence of death at 90 days post enrolment.
In patients recruited who are suspected to have COVID-19 disease the primary outcome will be “number of days alive and not admitted to ICU up to day 21
Timepoint: The occurrence of death will be collected between day 1 and day 90 from the time of enrolment into the trial until end of the hospital admission.
Other Endpoints
ICU Mortality
time_frame: Day 90
ICU length of stay
time_frame: Day 90
Hospital length of stay
time_frame: Day 90
Ventilator free days
time_frame: Day 28
Organ failure free days
time_frame: Day 28
Health-related Quality of life assessment
description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
time_frame: 6 months
Proportion of intubated patients who receive a tracheostomy
time_frame: Day 28
Destination at time of hospital discharge
description: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
time_frame: Free text Day 90
Readmission to the index ICU during the index hospitalization
time_frame: Day 90
World Health Organisation 8-point ordinal scale outcome
time_frame: Hospital discharge
Occurrence of multi-resistant organism colonisation/infection
description: Antibiotic Domain specific outcome
time_frame: Day 90, censored at hospital discharge
Occurrence clostridium difficile
description: Antibiotic Domain specific outcome
time_frame: Day 90, censored at hospital discharge
Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death
description: Macrolide Duration Domain specific outcome.
time_frame: Day 90, censored at hospital discharge
Change from baseline influenza virus levels in upper and lower respiratory tract specimens
description: Antiviral Domain specific outcome. Only required at selected sites.
time_frame: Day 3, up to Day 7
Confirmed deep vein thrombosis
description: Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
time_frame: Between randomisation and hospital discharge
Confirmed pulmonary embolism
description: Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
time_frame: Between randomisation and hospital discharge
Confirmed ischaemic cerebrovascular event
description: Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
time_frame: Between randomisation and hospital discharge
Total red blood cell units transfused
description: Domain-specific outcome for Anticoagulation and Antiplatelet Domains.
time_frame: Between randomisation and end of study day 15
Confirmed acute myocardial infarction
description: Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
time_frame: Between randomisation and hospital discharge
Peak troponin
description: Domain-specific outcome for Anticoagulation and Antiplatelet Domains.
time_frame: Between randomisation and end of study day 15
Major bleeding event
description: Domain-specific outcome for Anticoagulation and Antiplatelet Domains.
time_frame: Between randomisation and end of study day 15
Other confirmed thrombotic event, including mesenteric ischaemia and limb ischaemia
description: Domain-specific outcome for Anticoagulation, Immunoglobulin, and Antiplatelet Domains.
time_frame: Between randomisation and hospital discharge
Acute kidney injury (KDIGO stage ≥ 2 acute kidney injury)
description: Domain-specific outcome for ACE2 RAS Domain
time_frame: Between randomisation and 7 days
Change from baseline to peak creatinine
description: Domain-specific outcome for ACE2 RAS Domain
time_frame: Between randomisation and 14 days
Angioedema
description: Domain-specific outcome for ACE2 RAS Domain
time_frame: Between randomisation and end of study day 12
Change from baseline AST, ALT and bilirubin
description: Domain-specific outcome for ACE2 RAS Domain
time_frame: Between randomisation and 14 days [2]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
Community-acquired pneumonia | treatment | severe |
COVID 2019 infections | treatment | - |
COVID-19 pneumonia | treatment | severe |
Influenza virus infections | treatment | - |
SARS-CoV-2 acute respiratory disease | treatment | - |
Biomarker
NCT Number | Biomarker Name | Biomarker Function |
---|---|---|
NCT02735707 | ACE2 | Arm Group Label, Outcome Measure |
Ascorbic acid | Arm Group Description, Arm Group Label | |
Cardiac Troponin I | Outcome Measure | |
Cysteamine | Arm Group Description, Arm Group Label | |
purinergic receptor P2Y12 | Arm Group Description | |
RAS | Outcome Measure | |
Renin | Arm Group Description |
Subjects
- Subject Type patients
-
Number
Planned: 20000
Actual: 1557
- Sex male & female
- Age Group ≥ 18 years; adult; elderly
Patient Inclusion Criteria
REMAP-CAP PLATFORM 1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with: 1. symptoms or signs or both that are consistent with lower respiratory tract infection AND 2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate) 2. Up to 48 hours after ICU admission, receiving organ support with one or more of: 1. Non-invasive or Invasive ventilatory support; 2. Receiving infusion of vasopressor or inotropes or both PLATFORM
Patient Exclusion Criteria
1. Healthcare-associated pneumonia: 1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days 2. Resident of a nursing home or long term care facility 2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 3. Previous participation in this REMAP within the last 90 days REMAP-COVID PLATFORM INCLUSION CRITERIA 1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection. REMAP-COVID PLATFORM EXCLUSION CRITERIA 1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment 2. Patient is expected to be discharged from hospital today or tomorrow 3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection. 4. Previous participation in this REMAP within the last 90 days DOMAIN-SPECIFIC ELIGIBLE CRITERIA: Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT02735707 | ClinicalTrials.gov: US National Institutes of Health |
EudraCT2015-002340-14 | European Clinical Trials Database |
67000769 | ISRCTN: Current Controlled Trials |
UMIN000042594 | University Hospital Medical Information Network - Japan |
R000048462 | University Hospital Medical Information Network - Japan (Receipt No.) |
U1111-1189-1653 | World Health Organisation |
AD-SCAP | - |
602525 | - |
REMAP-CAP | - |
16-631 | - |
APP1101719 | - |
158584 | - |
CPMS38197IRAS237150 | - |
18LO0660 | - |
101003589 | - |
APP1116530 | - |
CTN2014-012 | - |
PHRC-20-0147 | - |
215522 | - |
RP-2015-06-18 | - |
CS-2016-16-011 | - |
Organisations
- Affiliations AbbVie; Amgen; Eisai Co Ltd; Faron Pharmaceuticals; NovaBiotics; Roche; Sanofi; Trevena
Trial Dates
-
Initiation Dates
Planned : 01 Jan 2021
Actual : 11 Apr 2016
-
Primary Completion Dates
Planned : 01 Feb 2026
-
End Dates
Planned : 01 Feb 2028
Substudies/Extensions
REMAP-COVID substudy : to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients.
Other Details
- Design multicentre; open; prospective; randomised
- Phase of Trial Phase III
- Location Australia; Austria; Belgium; Bosnia-Herzegovina; Canada; Colombia; Croatia; Czech Republic; Denmark; England; Estonia; Finland; France; Germany; Greece; Hungary; India; Ireland; Israel; Italy; Japan; Nepal; Netherlands; New Zealand; Pakistan; Portugal; Romania; Saudi Arabia; Serbia; Slovenia; Spain; Switzerland; United Kingdom; USA
- Focus Therapeutic Use
Interventions
Drugs | Route | Formulation |
---|---|---|
Amoxicillin/clavulanic acid | Intravenous | Injection |
AnakinraPrimary Drug | Intravenous | Infusion |
ApremilastPrimary Drug | Oral | Tablet |
Ascorbic acid | Intravenous | Injection |
Aspirin | Enteral | Tablet |
Azithromycin | Enteral | Tablet |
Azithromycin | Intravenous | Infusion |
Baloxavir-marboxil | Oral | Tablet |
Baricitinib | Oral | Tablet |
Ceftaroline fosamil | Intravenous | Infusion |
Ceftriaxone | Intravenous | Infusion, Injection |
Clarithromycin | Enteral | Tablet |
Clarithromycin | Intravenous | Infusion |
Clopidogrel | Enteral | Tablet |
Convalescent anti-SARS-CoV-2 plasma |
-
|
-
|
Dalteparin sodium | Intravenous | Injection |
Dalteparin sodium | Subcutaneous | Injection |
Dexamethasone | Enteral | Tablet |
Dexamethasone | Intravenous | Infusion, Injection |
EritoranPrimary Drug | Intravenous | Infusion |
Erythromycin | Intravenous | Infusion |
Heparin | Intravenous | Injection |
Hydrocortisone | Intravenous | Infusion, Injection |
HydroxychloroquinePrimary Drug | Enteral | Tablet |
Interferon beta-1 | Intravenous | Injection |
Interferon beta-1aPrimary Drug | Intravenous | Infusion, Injection |
Levofloxacin | Intravenous | Infusion |
Lopinavir | Enteral | Solution |
Lopinavir | Oral | Solution |
Lopinavir/ritonavirPrimary Drug | Enteral | Tablet |
Low molecular weight heparins | Subcutaneous |
-
|
Macrolides | Intravenous |
-
|
MercaptaminePrimary Drug | Intravenous |
-
|
Moxifloxacin | Intravenous | Infusion |
Oseltamivir | Enteral | Capsule |
Piperacillin/tazobactam | Intravenous | Injection |
Plasma |
-
|
-
|
Prasugrel | Enteral | Tablet |
Ritonavir | Enteral | Tablet |
Roxithromycin | Enteral | Tablet |
SarilumabPrimary Drug | Intravenous | Infusion |
Simvastatin | Enteral |
-
|
Ticagrelor | Enteral | Tablet |
TocilizumabPrimary Drug | Intravenous | Infusion |
TRV 027Primary Drug |
-
|
-
|
Vitamins | Intravenous |
-
|
Antibiotic Domain
Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions. Note: the ceftaroline + macrolide intervention has been closed to recruitment. Drug: Ceftriaxone (The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.) Drug: Moxifloxacin or Levofloxacin (The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.) Drug: Piperacillin-tazobactam (The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.) Drug: Ceftaroline (The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.) Drug: Amoxicillin-clavulanate (The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.)
Macrolide Duration Domain
Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy Drug: Standard course macrolide (Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5. The dosing of and route of administration is not protocolised, the following guidance is provided: Initial IV administration of a macrolide is strongly preferred The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.) Drug: Extended course macrolide (Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first). The dosing of and route of administration is not protocolised, the following guidance is provided: Initial IV administration of a macrolide is strongly preferred The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted. The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.)
Corticosteroid Domain
Patients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy. Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19. Other: No systemic corticosteroid (Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).) Drug: Fixed-duration Hydrocortisone (50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.) Drug: Shock-dependent hydrocortisone (50mg IV hydrocortisone every 6 hours while the patient is in septic shock) Drug: Fixed-duration higher dose Hydrocortisone (100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days. Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.) Drug: Fixed-duration dexamethasone (6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.)
Influenza Antiviral Domain
Patients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions. Other: No antiviral agent for influenza (No antiviral agent intended to be active against influenza infection is to be administered) Drug: Five-days oseltamivir (Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)) Drug: Ten-days oseltamivir (Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)) Drug: Baloxavir Marboxil (Baloxavir marboxil administered on days 1 and 4 post-randomisation.) Drug: Five-days oseltamivir + baloxavir marboxil (Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.) Drug: Ten-days oseltamivir + baloxavir marboxil (Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.)
COVID-19 Antiviral Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin. Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control. This domain is now closed. Other: No antiviral agent for COVID-19 (No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered) Drug: Lopinavir / Ritonavir (Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Note: this intervention is now closed.) Drug: Hydroxychloroquine (Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.) Drug: Hydroxychloroquine + lopinavir/ritonavir (Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU. Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first). Note: this intervention is now closed.) Drug: Ivermectin (Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.)
COVID-19 Immune Modulation Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions. Note: this domain is now closed. Other: No immune modulation for COVID-19 (No immune modulating agent intended to be active against COVID-19 is to be administered. Note: this intervention is now closed.) Drug: Interferon beta-1a (IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first. Note: this intervention is now closed.) Other Name: IFN-β1a Drug: Anakinra (A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours. In patients with renal impairment, anakinra will be administered on alternate days. Note: this intervention is now closed.) Drug: Tocilizumab (Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. Note: this intervention is now closed. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.) Drug: Sarilumab (Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period. Note: this intervention is now closed.)
Anticoagulation Domain
Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy. Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed. Drug: Local standard venous thromboprophylaxis (Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Note: this intervention is now closed.) Drug: Therapeutic dose anticoagulation (Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician. Note: this intervention is now closed.) Drug: Conventional low dose thromboprophylaxis (Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.) Drug: Intermediate dose thromboprophylaxis (Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.) Drug: Continuation of therapeutic dose anticoagulation (Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.)
Immunoglobulin Domain
Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma. Note: an earlier version of this domain was not restricted to immunosuppressed patients. Other: No immunoglobulin (No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered. Note: this intervention is now closed.) Biological: Convalescent plasma (Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation. Note: this intervention is now closed.) Biological: Delayed administration of convalescent plasma (Note: this intervention is now closed.)
Vitamin C Domain
Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C. Note: this domain is now closed. Other: No vitamin C (No high dose intravenous vitamin C is to be administered) Drug: Vitamin C (Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses)
Antiplatelet Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor. Note: this domain is now closed. Other: No antiplatelet (No antiplatelet agent or NSAID to be administered. Note: this intervention is now closed.) Drug: Aspirin (Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.) Other Name: acetylsalicylic acid Drug: P2Y12 inhibitor (Site-selected P2Y12 inhibitor: Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first. Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day. Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.) Other Name: Clopidogrel, Prasugrel, Ticagrelor
Simvastatin Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin. Note: this domain is now closed. Other: No simvastatin (No simvastatin intended to be active against COVID-19 is to be administered) Drug: Simvastatin (Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation)
COVID-19 Immune Modulation (2) Domain
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions. Note: this domain is now closed. Other: Placebo Drug: Eritoran (Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital) Drug: Apremilast (Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first. Note: this intervention is now closed.)
Mechanical Ventilation Domain
Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy Procedure: Clinician-preferred mechanical ventilation strategy (Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters) Procedure: Protocolised mechanical ventilation strategy (Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.)
ACE2 RAS Domain
Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies. Note: this domain is now closed. Other: No renin-angiotensin system inhibitor (No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.) Drug: Angiotensin converting enzyme inhibitor (Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.) Other Name: Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril Drug: Angiotensin Receptor Blockers (Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.) Other Name: Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan Drug: ARB + DMX-200 (Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first. ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.)
Cysteamine Domain
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine. Note: this domain is now closed. Other: No cysteamine (No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.) Drug: Cysteamine (Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.)
Endothelial Domain
Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib. Other: No endothelial modulator (No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.) Drug: Imatinib (Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.)
Influenza Immune Modulation
Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions. Other: No Immune Modulator for Influenza (No immune modulating agent intended to be active against influenza is to be administered.) Drug: Tocilizumab (Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg. Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.) Drug: Baricitinib (Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).)
COVID-19 Antiviral (II) Domain
Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions. Other: No antiviral agent for COVID-19 (No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered) Drug: Nirmatrelvir/ritonavir (Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.) Other Name: Paxlovid Drug: Remdesivir (Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.) Drug: Nirmatrelvir/ritonavir + remdesivir (Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.)
Results
Publications
-
Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2022;.
PubMed | CrossRef Fulltext -
Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. . JAMA 2021;.
PubMed | CrossRef Fulltext -
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive-Care-Med 2021;47(8):867-886.
PubMed | CrossRef Fulltext -
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. . N-Engl-J-Med 2021;.
PubMed | CrossRef Fulltext -
Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, et al. Simvastatin in Critically Ill Patients with Covid-19. . N-Engl-J-Med 2023;.
PubMed | CrossRef Fulltext -
Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. . N-Engl-J-Med 2021;.
PubMed | CrossRef Fulltext -
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N-Engl-J-Med 2021;.
PubMed | CrossRef Fulltext -
Goligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, et al. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA 2023;.
PubMed | CrossRef Fulltext -
Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. . JAMA 2023;329(14):1183-1196.
PubMed | CrossRef Fulltext -
Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. . JAMA 2020;.
PubMed | CrossRef Fulltext
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Adam Revill | Torbay and South Devon Hospital | United-Kingdom |
Adrian Donnelly, MD | Altnagelvin Hospital | United-Kingdom |
Ahmed Zaki | Stepping Hill Hospital | United-Kingdom |
Akram Khankhana, MD | Oregon Health and Science University | USA |
Alain Vuylsteke | Royal Papworth Hospital | United-Kingdom |
Alexandra Binnie, MD | William Osler Health System | Canada |
Alexis Turgeon, MD | CHU de Québec - Université Laval | Canada |
Alison Fox-Robichaud, MD | Hamilton general Hospital | Canada |
Alison Quinn | Royal Albert Edward Infirmary | United-Kingdom |
Alistair Nichol, Prof. | St. Vincent's University Hospital | Ireland |
Alistair Roy | South Tyneside District Hospital, Sunderland Hospital | United-Kingdom |
Amit Patel | The Christie Hospital | United-Kingdom |
Amro Katary | Queen's Hospital, Burton | United-Kingdom |
Ana Vujaklija Brajković, MD | University Hospital Centre Zagreb | Croatia |
Andrew Walden, MD | Royal Berkshire Hospital | United-Kingdom |
André Finn, MD | Charité - Universitätsmedizin Berlin - Nephrologie | Germany |
Aneela Kidwai, MD | Abbasi Shaheed Hospital | Pakistan |
Anil Hormis | Rotherham General Hospital | United-Kingdom |
Anish Mitra, MD | Surrey Memorial Hospital | Canada |
Anthony Gordon | St Mary's Hospital | United-Kingdom |
Antony Ashton, MD | Basingstoke and North Hampshire Hospital | United-Kingdom |
Arystarch Makowski | Medway Maritime Hospital | United-Kingdom |
Ashish Khanna, MD | Wake Forest Baptist Health | USA |
Barbara Borgatta | University Hospital Aintree | United-Kingdom |
Barbara Phillips | Royal Sussex County Hospital | United-Kingdom |
Basanta Gauli, MD | Chitwan Medical College | Nepal |
Ben Creagh-Brown | Royal Surrey County Hospital | United-Kingdom |
Bram Rochwerg, MD | Juravinski Hospital | Canada |
Brenda Reeve, MD | Brantford General Hospital | Canada |
Bruno Barsić, MD | University Hospital for Infectious Diseases | Croatia |
Béla Gál, MD | Csolnoky Ferenc Kórház - Veszprem County Hospital | Hungary |
Callum Kaye, MD | Aberdeen Royal Infirmary | United-Kingdom |
Cameron Green, MSc
info@remapcap.org
show details
|
-
|
|
Charlotte Small | Hereford County Hospital | United-Kingdom |
Charlotte Summers, MD | Addenbrookes Hospital | United-Kingdom |
Christopher Bassford, MD | University Hospital Coventry | United-Kingdom |
Christopher Day | Royal Devon and Exeter Hospital | United-Kingdom |
Colin McArthur, Dr | Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand |
-
|
Colin McArthur, MD | DCCM, Auckland City Hospital | New-Zealand |
Dan Harding | Queen Elizabeth Hospital, Woolwich | United-Kingdom |
Daniel Harvey | City Hospital Nottingham | United-Kingdom |
Daniel Harvey, MD | Queen's Medical Centre - Nottingham University Hospitals NHS Trust | United-Kingdom |
Daniel Smyth, MD | The Moncton Hospital | Canada |
David Antcliffe | Charing Cross Hospital | United-Kingdom |
David Golden, MD | Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust | United-Kingdom |
David Pogson, MD | Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust | United-Kingdom |
David Southern, MD | Wrexham Maelor Hospital | United-Kingdom |
David Yates | York Hospital | United-Kingdom |
Deborah Cook, MD | St. Joseph's Healthcare Hamilton | Canada |
Demetrios Kutsogiannis, MD | Royal Alexandra Hospital, Alberta | Canada |
Derek Angus, Prof | University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA |
-
|
Deva Jayakumar, MD | Apollo Speciality Hospital - OMR | India |
Dhinesh Sundaran | Kettering Hospital | United-Kingdom |
Dhruv Parekh | Queen Elizabeth Hospital Birmingham | United-Kingdom |
Dipak Mukherjee, MD | Basildon Hospital | United-Kingdom |
Diptesh Aryal, MD | Nepal Mediciti | Nepal |
Dirk Weismann, MD | Universitätsklinikum Würzburg | Germany |
Divya Khare | George Eliot Hospital | United-Kingdom |
Elankumaran Paramasivam, MD | Leeds Teaching Hospitals NHS Trust | United-Kingdom |
Elizabeth Wilcox, MD | Toronto Western Hospital | Canada |
Eric Sy, MD | Regina General Hospital | Canada |
Evert De Jonge, Prof. | Leiden University Medical Center | Netherlands |
Farooq Brohi, MD | University Hospital of North Tees | United-Kingdom |
Francois Lamontagne, MD | Centre Hospitalier de l'Université de Sherbrooke | Canada |
Francois Lellouche, MD | IUCPQ-UL | Canada |
Gary Mills | Northern General Hospital, Royal Hallamshire Hospital | United-Kingdom |
George Evetts | Frimley Park Hospital | United-Kingdom |
Ger Curley, Prof. | Beaumont Hospital | Ireland |
Gernot Rohde, Prof. Dr. | Universitätsklinikum Frankfurt | Germany |
Girendra Sadera | Arrow Park Hospital | United-Kingdom |
Gloria Vazquez-Grande, MD | Grace Hospital | Canada |
Gábor Szigligeti, MD | Jósa András County Hospital | Hungary |
Hadi Hatoum, MD | University of Florida | USA |
Hafiz Qureshi | Glenfield Hospital | United-Kingdom |
Hakeem Yusuff | Leicester Royal Infirmary | United-Kingdom |
Hem Paneru, MD | Hospital for Advanced Medicine and Surgery (HAMS) | Nepal |
Henrik Reschreiter, MD | Poole Hospital NHS Foundation Trust | United-Kingdom |
Ian Kerslake, MD | Royal United Hospital, Bath | United-Kingdom |
Ian McCullagh | Newcastle Freeman Hospital, Royal Victoria Infirmary, Newcastle | United-Kingdom |
Ingeborg Welters | Royal Liverpool Hospital | United-Kingdom |
Irina Grecu | Royal Hampshire Hospital | United-Kingdom |
James Limb, MD | Darlington Memorial Hospital, University Hospital of North Durham | United-Kingdom |
Jamie Gross | Northwick Park Hospital | United-Kingdom |
Jay Ritzema-Carter, MD | Christchurch Hospital | New-Zealand |
Jayaprakash Singh | Princess of Wales Hospital, Royal Glamorgan Hospital | United-Kingdom |
Jeffrey Jacobson, MD | University of Illinois Health | USA |
Jennifer Tsang, MD | Niagara Health | Canada |
Jeremy Bewley | Bristol Royal Hospital | United-Kingdom |
Jeremy Henning, MD | The James Cook University Hospital | United-Kingdom |
Jeroen Schouten, M.D. | Radboud University Medical Center | Netherlands |
Jeronimo Moreno-Cuesta | North Middlesex Hospital | United-Kingdom |
John Laffey, M.D. | University Hospital Galway | Ireland |
John Marshall, MD | St. Michael's Hospital Unity Health Toronto | Canada |
John Marshall, Prof | Unity Health Toronto, Study Chair REMAP-CAP Canada |
-
|
Jonathan Albrett, MD | Taranaki Base Hospital | New-Zealand |
Jonathan Bannardsmith | Manchester Royal Infirmary | United-Kingdom |
Jonathan Hulme | Birmingham City Hospital | United-Kingdom |
Jonathan Silversides | Mater Hospital, Royal Victoria Hospital, Belfast | United-Kingdom |
Jonathan Silversides, MD | Belfast City Hospital | United-Kingdom |
Jonathan Wilkinson, MD | Northampton General Hospital | United-Kingdom |
Jose Vazquez, MD | Augusta University | USA |
Joseph Carter, MD | York Hospital | United-Kingdom |
Joshua Denson, MD | Tulane Medical Center | USA |
Julius Centrum UMCU
Universiteitsweg 100
show details
Utrecht Postcode: 3584 Netherlands Telephone: +31(0)8875 681 81 juliuscenter@umcutrecht.nl |
University Medical Center Utrecht | Netherlands |
János Bélteczki, MD | Almási Balogh Pál Kórház | Hungary |
Kate Turner | Ipswich Hospital | United-Kingdom |
Kathryn Puxty | Glasgow Royal Infirmary | United-Kingdom |
Kevin Rooney | Royal Alexandra Hospital, Glasgow | United-Kingdom |
Koen Simons, M.D. | Jeroen Bosch Ziekenhuis | Netherlands |
Kosar Khwaja, MD | McGill University Health Centre | Canada |
Lars Pester | Universitätsklinikum Köln | Germany |
Laura van Gulik, M.D. | Meander Medisch Centrum | Netherlands |
Lauralyn McIntyre, MD | The Ottawa Hospital | Canada |
Lennie Derde, MD | University Medical Center Utrecht | Netherlands |
Lorenz Reill, MD | Vivantes Klinikum Neukölln | Germany |
Lorenzo del Sorbo, MD | Toronto General Hospital | Canada |
Madiha Hashmi, MD | Ziauddin University Hospital Clifton Campus | Pakistan |
Malcolm Sim | Queen Elizabeth University Hospital, Glasgow | United-Kingdom |
Malcolm Watters | Great Western Hospital | United-Kingdom |
Mandeep Phull | King George Hospital | United-Kingdom |
Manish Chablani | Lincoln County Hospital, Pilgrim's Hospital | United-Kingdom |
Manu Shankar-Hari | Guy's Hospital, St Thomas' Hospital | United-Kingdom |
Marc Bonten, Prof | UMC Utrecht, Study Chair REMAP-CAP Europe |
-
|
Marc Bourgeois, MD | AZ Sint-Jan | Belgium |
Mark Deneef | Royal Free Hospital | United-Kingdom |
Mark Saville | Southend University Hospital | United-Kingdom |
Martin Albert, MD | Hopital du Sacre-Coeur de Montreal | Canada |
Martin Schusterbruce, MD | Royal Bournemouth Hospital | United-Kingdom |
Martin Witzenrath, Prof. Dr. | Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie | Germany |
Mathias W. Pletz, Prof. Dr. | Universitätsklinikum Jena | Germany |
Matt Thomas, MD | Southmead Hospital | United-Kingdom |
Matt Wise | University Hospital of Wales | United-Kingdom |
Matthew Exline, MD | The Ohio State University Wexner Medical Center | USA |
Matthew Rowland | John Radcliffe Hospital | United-Kingdom |
Meghena Mathew, MD | Apollo First Med Hospital | India |
Michael Chasse, MD | Centre Hospitalier de l'Universite de Montreal | Canada |
Michael Karlikowski | James Paget Kings Lynn Hospital | United-Kingdom |
Michael Reay | Russells Hall Hospital | United-Kingdom |
Michael Spivey, MD | Royal Cornwall Hospital | United-Kingdom |
Mitchell Levy, MD | Brown University - Rhode Island Hospital | USA |
Mohamed Ramali | Colchester Hospital | United-Kingdom |
Nasir Khoso, MD | South City Hospital, Karachi | Pakistan |
Nawal Salahuddin, MD | National Institute of Cardiovascular Diseases, Karachi | Pakistan |
Nikitas Nikitas | Derriford Hospital | United-Kingdom |
Nunes Nunes, M.D. | Hospital Lusíadas Lisbon | Portugal |
Nuno Catorze, M.D. | Centro Hospitalar do Medio Tejo | Portugal |
Oana Cole | Liverpool Heart and Chest Hospital | United-Kingdom |
Olivia Kelsall, MD | Alexandra Hospital, Redditch | United-Kingdom |
Omar Touma | Wexham Park Hospital | United-Kingdom |
Oscar Hoiting, M.D. | Canisius Wilhelmina Ziekenhuis | Netherlands |
Patrick Archambault, MD | CIUSS Chaudieres-Appalaches (Levis) | Canada |
Patrick Biston, MD | CHU de Charleroi - Hôpital Civil Marie Curie | Belgium |
Paul Dark | Salford Royal Hospital | United-Kingdom |
Paul Johnston, MD | Antrim Area Hospital | United-Kingdom |
Paul Pulak | King's Mill Hospital | United-Kingdom |
Paul Young, MD | Wellington Regional Hospital | New-Zealand |
Pauline Austin | Ninewells Hospital | United-Kingdom |
Peter Alexander | Wythenshawe Hospital | United-Kingdom |
Peter Bamford | Countess of Chester Hospital | United-Kingdom |
Phil Donnison | Salisbury District Hospital | United-Kingdom |
Philippe Jorens, Prof. | Universitair Ziekenhuis Antwerp | Belgium |
Pieter Depuydt, Prof. | Universitair Ziekenhuis Gent | Belgium |
Prijesh Patel | Ryal Brompton | United-Kingdom |
Quratul Ain, MD | Ziauddin University North Nazimabad Campus | Pakistan |
Rafael Leon-Lopez, M.D. | Hospital Universitario Reina Sofia | Spain |
Rajeev Jha, MD | Barnet Hospital | United-Kingdom |
Ralph Fuchs, MD | Whangarei Hospital | New-Zealand |
Ramprasad Matsa | Royal Stoke University Hospital | United-Kingdom |
Rebecca Kruisselbrink, MD | St Mary's General Hospital | Canada |
Redmond Tully | Royal Oldham Hospital | United-Kingdom |
Reena Mehta | King's College Hospital | United-Kingdom |
Richard Innes | Musgrove Park Hospital | United-Kingdom |
Richard Pugh, MD | Glan Clywd Hospital | United-Kingdom |
Richard Stewart, MD | Milton Keynes University Hospital | United-Kingdom |
Rob Fowler, MD | Sunnybrook Health Sciences Centre | Canada |
Robert Everitt, MD | North Shore Hospital | New-Zealand |
Robert Hyzy, MD | University of Michigan | USA |
Robert Martynoga, MD | Waikato Hospital | New-Zealand |
Rosana Munoz, M.D. | Institut Hospital del Mar d'Investigacions Mèdiques | Spain |
Ryan Zarychanski, MD | Health Sciences Centre Winnipeg, St Boniface General Hospital | Canada |
Sangeeta Mehta, MD | Mount Sinai Hospital | Canada |
Sarah Beavis | Chesterfield Royal Hospital | United-Kingdom |
Sascha David, MD | Medizinische Hochschule Hannover | Germany |
Shaman Jhanji | Royal Marsden Hospital | United-Kingdom |
Shameer Gopala Pillai | New Cross Hospital | United-Kingdom |
Shay McGuinness, MD | CVICU, Auckland City Hospital | New-Zealand |
Shigeki Fujitani
Department of Emergency and Critical Care Medicine
show details
2-16-1 Sugao Miyamae-ku, Kawasaki-shi, Kanagawa 216-8511 Japan ZIP CIDE: 216-8511 Telephone: 044-977-8111 shigekifujitani@marianna-u.ac.jp Homepage URL: https://www.remapcap.jp |
St. Marianna University School of Medicine |
-
|
Shondipon Laha | Royal Preston Hospital | United-Kingdom |
Simin-Aysel Florescu, MD | Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes" | Romania |
Simon Fletcher | Norfolk and Norwich University Hospital | United-Kingdom |
Sirak Petros, Prof. Dr. | Universitätsklinikum Leipzig | Germany |
Siri Göpel, MD | Universitäts Klinikum Tübingen | Germany |
Srikanth Chukkambotla, MD | Blackburn Hospital | United-Kingdom |
Stefan Klug, Prof. Dr. | University Medical Center Hamburg-Eppendorf (UKE) | Germany |
Stephanie Mongomery | University of Pittsburgh Medical Centre | USA |
Stephen Brett | Hammersmith Hospital | United-Kingdom |
Stephen Digby | Worcester Royal Hospital | United-Kingdom |
Stephen McWilliam, MD | Alder Hey Hospital | United-Kingdom |
Stephen Pastores, MD | Memorial Sloan Kettering Cancer Center | USA |
Stephen Robinson, MD | The Saint John General Hospital | Canada |
Steve Webb, Prof | Monash University, Study Chair REMAP-CAP Australia |
-
|
Sundar Ashok | Croydon University Hospital | United-Kingdom |
Sureshkumar Gopala Pillai | Morriston Hospital | United-Kingdom |
Susannah Leaver | St George's Hospital | United-Kingdom |
Sushil Khanal, MD | Grande International Hospital | Nepal |
Svenja Peters, MSc
EU.remapcap@umcutrecht.nl
show details
|
-
|
|
Tamas Szakmany, MD | Grange University Hospital | United-Kingdom |
Theresa Liu, MD | Grand River Hospital | Canada |
Thomas Craven | Royal Infirmary of Edinburgh | United-Kingdom |
Thomas Hemmerling, MD | Hôpital Fleury | Canada |
Thomas William | Princess Royal University Hospital | United-Kingdom |
Tim Smith | Cumberland Royal Infirmary, West Cumberland Hospital | United-Kingdom |
Tony Williams, MD | Middlemore Hospital | New-Zealand |
Troy Browne, MD | Tauranga Hospital | New-Zealand |
Ulrike Buehner, MD | Rotorua Hospital | New-Zealand |
Valarie Page | Watford General Hospital | United-Kingdom |
Vanessa Linnett | Queen Elizabeth Hospital | United-Kingdom |
Wendy Sligl, MD | University of Alberta Hospital | Canada |
Yaseen Arabi, MD | King Abdulaziz Medical City | Saudi-Arabia |
Yvonne Plesnikova | Glangwilli Hospital | United-Kingdom |
Zdravko Andrić, MD | General County Hospital Požega | Croatia |
Zeeshan Aslam, MD | Dr. Everett Chalmers Regional Hospital | Canada |
Zoe Borrill | North Manchester General Hospital | United-Kingdom |
Zudin Puthucheary, MD | Newham Hospital, Royal London Hospital, St Barts Hosptial, Whipps Cross Hospital | United-Kingdom |
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
- |
-
|
-
|
Abbasi Shaheed Hospital | Karachi, Sindh | Pakistan |
Aberdeen Royal Infirmary | Aberdeen, Scotland | United-Kingdom |
Addenbrookes Hospital | Cambridge, England | United-Kingdom |
Alder Hey Hospital | Liverpool, England | United-Kingdom |
Alexandra Hospital, Redditch | Redditch, England | United-Kingdom |
Almási Balogh Pál Kórház | Ózd | Hungary |
Altnagelvin Hospital | Derry, Northern Ireland | United-Kingdom |
Angliss Hospital | Ferntree Gully, Victoria | Australia |
Antrim Area Hospital | Antrim, Northern Ireland | United-Kingdom |
Apollo First Med Hospital | Chennai, Tamil Nadu | India |
Apollo Main Hospital | Chennai, Tamil Nadu | India |
Apollo Speciality Hospital - OMR | Chennai, Tamil Nadu | India |
Apollo Vanagaram Hospital | Chennai, Tamil Nadu | India |
Arrow Park Hospital | Wirral, England | United-Kingdom |
Ashford & St Peters Hospital Trust | Chertsey, England | United-Kingdom |
Augusta University | Augusta, Georgia | USA |
Australian and New Zealand Intensive Care Research Centre |
-
|
-
|
AZ Sint-Jan | Brugge | Belgium |
Ballarat Base Hospital | Ballarat, Victoria | Australia |
Bankstown-Lidcombe Hospital | Bankstown, New South Wales | Australia |
Barnet Hospital | High Barnet, England | United-Kingdom |
Basildon Hospital | Basildon, England | United-Kingdom |
Basingstoke and North Hampshire Hospital | Basingstoke, England | United-Kingdom |
Beaumont Hospital | Dublin | Ireland |
Belfast City Hospital | Belfast, Northern Ireland | United-Kingdom |
Bendigo Hospital | Bendigo, Victoria | Australia |
Berry Consultants |
-
|
-
|
Birmingham City Hospital | Birmingham, England | United-Kingdom |
Blackburn Hospital | Blackburn, England | United-Kingdom |
Blacktown Hospital | Blacktown, New South Wales | Australia |
Box Hill Hospital | Box Hill, Victoria | Australia |
Brantford General Hospital | Brantford, Ontario | Canada |
Bristol Royal Hospital | Bristol, England | United-Kingdom |
Brown University - Rhode Island Hospital | Providence, Rhode Island | USA |
Caboolture Hospital | Caboolture, Queensland | Australia |
Campbelltown Hospital | Campbelltown, New South Wales | Australia |
Canberra Hospital | Canberra, Australian Capital Territory | Australia |
Canisius Wilhelmina Ziekenhuis | Nijmegen | Netherlands |
Casey Hospital | Berwick, Victoria | Australia |
Centre Hospitalier de l'Universite de Montreal | Montréal, Quebec | Canada |
Centre Hospitalier de l'Université de Sherbrooke | Sherbrooke, Quebec | Canada |
Centro Hospitalar do Medio Tejo | Abrantes | Portugal |
Charing Cross Hospital | London, England | United-Kingdom |
Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie | Berlin | Germany |
Charité - Universitätsmedizin Berlin - Nephrologie | Berlin | Germany |
Chesterfield Royal Hospital | Chesterfield, England | United-Kingdom |
Chitwan Medical College | Bharatpur | Nepal |
Christchurch Hospital | Christchurch | New-Zealand |
CHU de Charleroi - Hôpital Civil Marie Curie | Charleroi | Belgium |
CHU de Québec - Université Laval | Québec, Quebec | Canada |
City Hospital Nottingham | Nottingham, England | United-Kingdom |
CIUSS Chaudieres-Appalaches (Levis) | Lévis, Quebec | Canada |
Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes" | Bucharest | Romania |
Colchester Hospital | Colchester, England | United-Kingdom |
Concord Hospital | Concord, New South Wales | Australia |
Countess of Chester Hospital | Chester, England | United-Kingdom |
Croydon University Hospital | London, England | United-Kingdom |
Csolnoky Ferenc Kórház - Veszprem County Hospital | Veszprém | Hungary |
Cumberland Royal Infirmary | Carlisle, England | United-Kingdom |
CVICU, Auckland City Hospital | Auckland | New-Zealand |
Dandenong Hospital | Dandenong, Victoria | Australia |
Darent Valley Hospital | Dartford, England | United-Kingdom |
Darlington Memorial Hospital | Darlington, England | United-Kingdom |
DCCM, Auckland City Hospital | Auckland | New-Zealand |
Derriford Hospital | Plymouth, England | United-Kingdom |
Dr. Everett Chalmers Regional Hospital | Fredericton, New Brunswick | Canada |
Dubbo Base Hospital | Dubbo, New South Wales | Australia |
Fiona Stanley Hospital | Perth, Western Australia | Australia |
Flinders Medical Centre | Bedford Park, South Australia | Australia |
Foothills Medical Centre | Calgary, Alberta | Canada |
Footscray Hospital | Footscray, Victoria | Australia |
FP7-HEALTH-2013-INNOVATION-1 |
-
|
European-Union |
Frimley Park Hospital | Frimley, England | United-Kingdom |
General County Hospital Požega | Požega | Croatia |
George Eliot Hospital | Nuneaton, England | United-Kingdom |
Glan Clywd Hospital | Bodelwyddan, Wales | United-Kingdom |
Glangwilli Hospital | Carmarthen, Wales | United-Kingdom |
Glasgow Royal Infirmary | Glasgow, Scotland | United-Kingdom |
Glenfield Hospital | Leicester, England | United-Kingdom |
Global Coalition for Adaptive Research |
-
|
-
|
Gold Coast University Hospital | Southport, Queensland | Australia |
Grace Hospital | Winnipeg, Manitoba | Canada |
Grand River Hospital | Kitchener, Ontario | Canada |
Grande International Hospital | Kathmandu | Nepal |
Grange University Hospital | Cwmbran, Wales | United-Kingdom |
Great Western Hospital | Swindon, England | United-Kingdom |
Guy's Hospital | London, England | United-Kingdom |
Hamilton general Hospital | Hamilton, Ontario | Canada |
Hammersmith Hospital | London, England | United-Kingdom |
Harefield Hospital | Uxbridge, England | United-Kingdom |
Health Sciences Centre Winnipeg | Winnipeg, Manitoba | Canada |
Hereford County Hospital | Hereford, England | United-Kingdom |
Hopital du Sacre-Coeur de Montreal | Montréal, Quebec | Canada |
Hospital for Advanced Medicine and Surgery (HAMS) | Kathmandu | Nepal |
Hospital Lusíadas Lisbon | Lisboa | Portugal |
Hospital Maisonneuve-Rosemont | Montréal, Quebec | Canada |
Hospital Universitario Reina Sofia | Córdoba | Spain |
Huddersfield Hospital | Huddersfield, England | United-Kingdom |
Hôpital Fleury | Montréal, Quebec | Canada |
Institut Hospital del Mar d'Investigacions Mèdiques | Barcelona | Spain |
Intensive Care National Audit & Research Centre |
-
|
-
|
Ipswich Hospital | Ipswich, England | United-Kingdom |
Itabashi Chuo Medical Center | Tokyo | Japan |
IUCPQ-UL | Québec, Quebec | Canada |
James Paget Kings Lynn Hospital | Great Yarmouth, England | United-Kingdom |
Jeroen Bosch Ziekenhuis | Den Bosch | Netherlands |
John Hunter Hospital | Newcastle, New South Wales | Australia |
John Radcliffe Hospital | Oxford, England | United-Kingdom |
Juravinski Hospital | Hamilton, Ontario | Canada |
Jósa András County Hospital | Nyíregyháza | Hungary |
Kettering Hospital | Kettering, England | United-Kingdom |
King Abdulaziz Medical City | Riyadh | Saudi-Arabia |
King George Hospital | Ilford, England | United-Kingdom |
King's College Hospital | London, England | United-Kingdom |
King's Mill Hospital | Sutton In Ashfield, England | United-Kingdom |
Kingston Health Sciences Centre | Kingston, Ontario | Canada |
Launceston Hospital | Launceston, Tasmania | Australia |
Leeds Teaching Hospitals NHS Trust | Leeds, England | United-Kingdom |
Leicester Royal Infirmary | Leicester, England | United-Kingdom |
Leiden University Medical Center | Leiden | Netherlands |
Lincoln County Hospital | Lincoln, England | United-Kingdom |
Liverpool Heart and Chest Hospital | Liverpool, England | United-Kingdom |
Liverpool Hospital | Liverpool, New South Wales | Australia |
Logan Hospital | Logan, Queensland | Australia |
Luton and Dunstable University Hospital | Luton, England | United-Kingdom |
Lyell McEwin Hospital | Adelaide, South Australia | Australia |
Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust | Maidstone, England | United-Kingdom |
Manchester Royal Infirmary | Manchester, England | United-Kingdom |
Maroondah Hospital | Ringwood East, Victoria | Australia |
Martini Hospital Groningen | Groningen | Netherlands |
Mater Hospital | Belfast, Northern Ireland | United-Kingdom |
Mater Hospital Brisbane | Brisbane, Queensland | Australia |
McGill University Health Centre | Montréal, Quebec | Canada |
Meander Medisch Centrum | Amersfoort | Netherlands |
Medical Research Institute of New Zealand |
-
|
-
|
Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand |
-
|
-
|
Medizinische Hochschule Hannover | Hannover | Germany |
Medway Maritime Hospital | Gillingham, England | United-Kingdom |
Memorial Sloan Kettering Cancer Center | New York, New York | USA |
Middlemore Hospital | Auckland | New-Zealand |
Milton Keynes University Hospital | Milton Keynes, England | United-Kingdom |
MJM Bonten |
-
|
-
|
Monash Medical Centre | Clayton, Victoria | Australia |
Monash University, Study Chair REMAP-CAP Australia |
-
|
-
|
Morriston Hospital | Swansea, Wales | United-Kingdom |
Mount Sinai Hospital | Toronto, Ontario | Canada |
Musgrove Park Hospital | Taunton, England | United-Kingdom |
National Institute of Cardiovascular Diseases, Karachi | Karachi, Sindh | Pakistan |
National Intensive Care Surveillance MORU |
-
|
-
|
National University Hospital, Singapore |
-
|
-
|
Nepal Mediciti | Kathmandu | Nepal |
Nepean Hospital | Kingswood, New South Wales | Australia |
Nerima Hikarigaoka Hospital | Tokyo | Japan |
Neville Hall Hospital | Abergavenny, Wales | United-Kingdom |
New Cross Hospital | Wolverhampton, England | United-Kingdom |
Newcastle Freeman Hospital | Newcastle, England | United-Kingdom |
Newham Hospital | London, England | United-Kingdom |
Niagara Health | Saint Catharines, Ontario | Canada |
Ninewells Hospital | Dundee, Scotland | United-Kingdom |
Norfolk and Norwich University Hospital | Norwich, England | United-Kingdom |
North Manchester General Hospital | Crumpsall, England | United-Kingdom |
North Middlesex Hospital | London, England | United-Kingdom |
North Shore Hospital | Auckland | New-Zealand |
Northampton General Hospital | Northampton, England | United-Kingdom |
Northern Beaches Hospital | Frenchs Forest, New South Wales | Australia |
Northern General Hospital | Sheffield, England | United-Kingdom |
Northwick Park Hospital | Harrow, England | United-Kingdom |
Orange Health Service | Orange, New South Wales | Australia |
Oregon Health and Science University | Portland, Oregon | USA |
Osaka City General Hospital | Osaka | Japan |
Peter Lougheed Centre | Calgary, Alberta | Canada |
Pilgrim's Hospital | Boston, England | United-Kingdom |
Poole Hospital NHS Foundation Trust | Poole, England | United-Kingdom |
Prince of Wales Hospital | Sydney, New South Wales | Australia |
Princess Alexandra Hospital | Brisbane, Queensland | Australia |
Princess of Wales Hospital | Bridgend, Wales | United-Kingdom |
Princess Royal University Hospital | Orpington, England | United-Kingdom |
Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust | Portsmouth, England | United-Kingdom |
Queen Elizabeth Hospital | Gateshead, England | United-Kingdom |
Queen Elizabeth Hospital Birmingham | Birmingham, England | United-Kingdom |
Queen Elizabeth Hospital, Woolwich | Margate, England | United-Kingdom |
Queen Elizabeth II Jubilee Hospital | Coopers Plains, Queensland | Australia |
Queen Elizabeth University Hospital, Glasgow | Glasgow, Scotland | United-Kingdom |
Queen's Hospital Romford | Romford, England | United-Kingdom |
Queen's Hospital, Burton | Burton on Trent, England | United-Kingdom |
Queen's Medical Centre - Nottingham University Hospitals NHS Trust | Nottingham, England | United-Kingdom |
Radboud University Medical Center | Nijmegen | Netherlands |
Redcliffe Hospital | Redcliffe, Queensland | Australia |
Regina General Hospital | Saskatoon, Saskatchewan | Canada |
Rockhampton Hospital | Rockhampton, Queensland | Australia |
Rockyview General Hospital | Calgary, Alberta | Canada |
Rotherham General Hospital | Rotherham, England | United-Kingdom |
Rotorua Hospital | Rotorua | New-Zealand |
Royal Adelaide Hospital | Adelaide, South Australia | Australia |
Royal Albert Edward Infirmary | Wigan, England | United-Kingdom |
Royal Alexandra Hospital, Alberta | Edmonton, Alberta | Canada |
Royal Alexandra Hospital, Glasgow | Paisley, Scotland | United-Kingdom |
Royal Berkshire Hospital | Reading, England | United-Kingdom |
Royal Bournemouth Hospital | Bournemouth, England | United-Kingdom |
Royal Cornwall Hospital | Truro, England | United-Kingdom |
Royal Darwin Hospital, | Darwin, Northern Territory | Australia |
Royal Devon and Exeter Hospital | Exeter, England | United-Kingdom |
Royal Free Hospital | London, England | United-Kingdom |
Royal Glamorgan Hospital | Pontyclun, Wales | United-Kingdom |
Royal Gwent Hospital | Newport, Wales | United-Kingdom |
Royal Hallamshire Hospital | Sheffield, England | United-Kingdom |
Royal Hampshire Hospital | Winchester, England | United-Kingdom |
Royal Infirmary of Edinburgh | Edinburgh, Scotland | United-Kingdom |
Royal Liverpool Hospital | Liverpool, England | United-Kingdom |
Royal London Hospital | London, England | United-Kingdom |
Royal Marsden Hospital | London, England | United-Kingdom |
Royal Melbourne Hospital | Melbourne, Victoria | Australia |
Royal North Shore Hospital | Sydney, New South Wales | Australia |
Royal Oldham Hospital | Oldham, England | United-Kingdom |
Royal Papworth Hospital | Cambridge, England | United-Kingdom |
Royal Perth Hospital | Perth, Western Australia | Australia |
Royal Preston Hospital | Preston, England | United-Kingdom |
Royal Prince Alfred Hospital | Sydney, New South Wales | Australia |
Royal Stoke University Hospital | Stoke-on-Trent, England | United-Kingdom |
Royal Surrey County Hospital | Guildford, England | United-Kingdom |
Royal Sussex County Hospital | Brighton, England | United-Kingdom |
Royal United Hospital, Bath | Bath, England | United-Kingdom |
Royal Victoria Hospital, Belfast | Belfast, Northern Ireland | United-Kingdom |
Royal Victoria Infirmary, Newcastle | Newcastle, England | United-Kingdom |
Russells Hall Hospital | Dudley, England | United-Kingdom |
Ryal Brompton | London, England | United-Kingdom |
Saiseikai Kumamoto Hospital | Minami, Kumamoto | Japan |
Salford Royal Hospital | Salford, England | United-Kingdom |
Salisbury District Hospital | Salisbury, England | United-Kingdom |
Sir Charles Gairdner Hospital | Perth, Western Australia | Australia |
South City Hospital, Karachi | Karachi, Sindh | Pakistan |
South Health Campus | Calgary, Alberta | Canada |
South Tyneside District Hospital | South Shields, England | United-Kingdom |
Southampton General Hospital | Southampton, England | United-Kingdom |
Southend University Hospital | Westcliff-on-Sea, England | United-Kingdom |
Southmead Hospital | Bristol, England | United-Kingdom |
St Barts Hosptial | London, England | United-Kingdom |
St Boniface General Hospital | Winnipeg, Manitoba | Canada |
St George's Hospital | London, England | United-Kingdom |
St John of God Hospital Midland | Midland, Western Australia | Australia |
St John of God Hospital Murdoch | Murdoch, Western Australia | Australia |
St John of God Subiaco | Subiaco, Western Australia | Australia |
St Joseph's Health Centre | Toronto, Ontario | Canada |
St Marianna University School of Medicine | Kawasaki, Kanagawa | Japan |
St Mary's General Hospital | Kitchener, Ontario | Canada |
St Mary's Hospital | London, England | United-Kingdom |
St Thomas' Hospital | London, England | United-Kingdom |
St Vincent's Hospital Melbourne | Melbourne, Victoria | Australia |
St Vincent's Hospital Sydney | Sydney, New South Wales | Australia |
St. George Hospital | Kogarah, New South Wales | Australia |
St. Joseph's Healthcare Hamilton | Hamilton, Ontario | Canada |
St. Marianna University School of Medicine |
-
|
-
|
St. Marianna University School of Medicine |
-
|
-
|
St. Marianna University Yokohama City Seibu Hospital | Yokohama, Kanagawa | Japan |
St. Michael's Hospital Unity Health Toronto | Toronto, Ontario | Canada |
St. Vincent's University Hospital | Dublin | Ireland |
Stepping Hill Hospital | Stockport, England | United-Kingdom |
Sunderland Hospital | Sunderland, England | United-Kingdom |
Sunnybrook Health Sciences Centre | Toronto, Ontario | Canada |
Sunshine Coast University Hospital | Birtinya, Queensland | Australia |
Sunshine Hospital | Sunshine, Victoria | Australia |
Surrey Memorial Hospital | Surrey, British Columbia | Canada |
Sutherland Hospital | Caringbah, New South Wales | Australia |
Taranaki Base Hospital | New Plymouth | New-Zealand |
Tauranga Hospital | Tauranga | New-Zealand |
The Alfred Hospital | Melbourne, Victoria | Australia |
The Christie Hospital | Manchester, England | United-Kingdom |
The James Cook University Hospital | Middlesbrough, England | United-Kingdom |
The Moncton Hospital | Fredericton, New Brunswick | Canada |
The Ohio State University Wexner Medical Center | Columbus, Ohio | USA |
The Ottawa Hospital | Ottawa, Ontario | Canada |
The Prince Charles Hospital | Brisbane, Queensland | Australia |
The Queen Elizabeth Hospital | Adelaide, South Australia | Australia |
The Saint John General Hospital | Fredericton, New Brunswick | Canada |
Thunder Bay General Hospital | Thunder Bay, Ontario | Canada |
Tokyo bay Urayasu-Ichikawa Medical Center | Tokyo | Japan |
Tokyo Metropolitan Bokutoh Hospital | Tokyo | Japan |
Toowoomba Hospital | Toowoomba, Queensland | Australia |
Torbay and South Devon Hospital | Torquay, England | United-Kingdom |
Toronto General Hospital | Toronto, Ontario | Canada |
Toronto Western Hospital | Toronto, Ontario | Canada |
Townsville Hospital | Townsville, Queensland | Australia |
Tulane Medical Center | New Orleans, Louisiana | USA |
Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust | Tunbridge Wells, England | United-Kingdom |
UMC Utrecht, Study Chair REMAP-CAP Europe |
-
|
-
|
Unity Health |
-
|
-
|
Unity Health Toronto, Study Chair REMAP-CAP Canada |
-
|
-
|
Universidad de La Sabana | Chía, Cundinamarca | Colombia |
Universitair Ziekenhuis Antwerp | Edegem | Belgium |
Universitair Ziekenhuis Gent | Gent | Belgium |
University Hospital Aintree | Liverpool, England | United-Kingdom |
University Hospital Centre Zagreb | Zagreb | Croatia |
University Hospital Coventry | Coventry, England | United-Kingdom |
University Hospital for Infectious Diseases | Zagreb | Croatia |
University Hospital Galway | Galway | Ireland |
University Hospital of North Durham | Durham, England | United-Kingdom |
University Hospital of North Tees | Stockton-on-Tees, England | United-Kingdom |
University Hospital of Wales | Cardiff, Wales | United-Kingdom |
University Hosptial Geelong | Geelong, Victoria | Australia |
University Medical Center Groningen | Groningen | Netherlands |
University Medical Center Hamburg-Eppendorf (UKE) | Hamburg | Germany |
University Medical Center Utrecht | Utrecht | Netherlands |
University Medical Center Utrecht | Utrecht | Netherlands |
University of Alberta Hospital | Edmonton, Alberta | Canada |
University of Florida | Jacksonville, Florida | USA |
University of Illinois Health | Chicago, Illinois | USA |
University of Michigan | Ann Arbor, Michigan | USA |
University of Pittsburgh Medical Center |
-
|
-
|
University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA |
-
|
-
|
University of Pittsburgh Medical Centre | Pittsburgh, Pennsylvania | USA |
Universitäts Klinikum Tübingen | Tübingen | Germany |
Universitätsklinikum Frankfurt | Frankfurt | Germany |
Universitätsklinikum Jena | Jena | Germany |
Universitätsklinikum Köln | Cologne | Germany |
Universitätsklinikum Leipzig | Leipzig | Germany |
Universitätsklinikum Würzburg | Würzburg | Germany |
Vivantes Klinikum Neukölln | Berlin | Germany |
Wagga Wagga Base Hospital | Wagga Wagga, New South Wales | Australia |
Waikato Hospital | Hamilton | New-Zealand |
Wakayama Medical University | Wakayama | Japan |
Wake Forest Baptist Health | Winston-Salem, North Carolina | USA |
Watford General Hospital | Watford, England | United-Kingdom |
Wellington Regional Hospital | Wellington | New-Zealand |
Werribee Mercy Hospital | Werribee, Victoria | Australia |
West Cumberland Hospital | Whitehaven, England | United-Kingdom |
Western General Hospital | Swindon, England | United-Kingdom |
Westmead Hospital | Westmead, New South Wales | Australia |
Wexham Park Hospital | Slough, England | United-Kingdom |
Whangarei Hospital | Whangarei | New-Zealand |
Whipps Cross Hospital | London, England | United-Kingdom |
Whiston Hospital | Prescot, England | United-Kingdom |
William Osler Health System | Brampton, Ontario | Canada |
Wollongong Hospital | Sydney, New South Wales | Australia |
Worcester Royal Hospital | Worcester, England | United-Kingdom |
Wrexham Maelor Hospital | Wrexham, Wales | United-Kingdom |
Wythenshawe Hospital | Manchester, England | United-Kingdom |
Yokohama City University Hospital | Yokohama, Kanagawa | Japan |
York Hospital | York, England | United-Kingdom |
Ziauddin University Hospital Clifton Campus | Karachi, Sindh | Pakistan |
Ziauddin University North Nazimabad Campus | Karachi, Sindh | Pakistan |
Trial History
Event Date | Event Type | Comment |
---|---|---|
08 Apr 2024 | Other trial event | Last checked against European Clinical Trials Database record. Updated 08 Apr 2024 |
01 Mar 2024 | Other trial event | Last checked against ClinicalTrials.gov record. Updated 01 Mar 2024 |
25 Oct 2023 | Results | Results published in the New England Journal of Medicine Updated 01 Nov 2023 |
12 Sep 2023 | Other trial event | Planned number of patients changed from 10000 to 20000. Updated 13 Sep 2023 |
01 Jun 2023 | Completion date | Planned End Date changed from 1 Dec 2025 to 1 Feb 2028. Updated 07 Jun 2023 |
01 Jun 2023 | Other trial event | Planned primary completion date changed from 1 Dec 2023 to 1 Feb 2026. Updated 07 Jun 2023 |
11 Apr 2023 | Results | Results(n=779) assessing Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19 published in the JAMA: the Journal of the American Medical Association Updated 14 Apr 2023 |
12 Mar 2023 | Results | Results of exploratory analysis (n=3320) assessing the heterogeneity of treatment effect of therapeutic-dose heparin for patients hospitalized for COVID-19 and to compare approaches to assessing heterogeneity of treatment effect, published in the JAMA: the Journal of the American Medical Association. Updated 24 Mar 2023 |
12 Dec 2022 | Other trial event | Last checked against ISRCTN: Current Controlled Trials record. Updated 12 Dec 2022 |
19 May 2022 | Other trial event | According to a Global Coalition for Adaptive Research media release, company has ended the evaluation of eritoran in the REMAP-COVID study. The decision to terminate the evaluation was due to changes in the COVID-19 landscape. Updated 25 May 2022 |
28 Apr 2022 | Other trial event | This trial has been suspended in Spain according to European Clinical Trials Database record. Updated 28 Apr 2022 |
25 Mar 2022 | Status change - discontinued | Status has been changed to discontinued, as per results published in the JAMA: the Journal of the American Medical Association Updated 25 Mar 2022 |
22 Mar 2022 | Endpoint met | Primary endpoint has been met. (organ supportfree days), as per published in the JAMA: the Journal of the American Medical Association Updated 25 Mar 2022 |
22 Mar 2022 | Results | Results assessing whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19, published in the JAMA: the Journal of the American Medical Association Updated 25 Mar 2022 |
03 Feb 2022 | Other trial event | Last checked against ISRCTN: Current Controlled Trials record. Updated 03 Feb 2022 |
21 Dec 2021 | Biomarker Update | Biomarkers information updated Updated 23 Dec 2021 |
08 Dec 2021 | Other trial event | According to a NovaBiotics media release, the company expect that top-line data from this study will be available in 2022 and look forward to pursuing goal of this study to serve as a registration study. Updated 14 Dec 2021 |
08 Dec 2021 | Other trial event | According to a NovaBiotics media release, the company has produced NM002 doses for the initial UK phase of REMAP-CAP and has developed a scalable manufacturing process for NM002 to supply the balance of the trial. Updated 14 Dec 2021 |
08 Dec 2021 | Other trial event | According to a NovaBiotics media release, first patient has been enrolled in this study. Updated 14 Dec 2021 |
03 Dec 2021 | Other trial event | Planned number of patients changed from 7100 to 10000. Updated 28 Dec 2021 |
03 Dec 2021 | Completion date | Planned End Date changed from 1 Dec 2023 to 1 Dec 2025. Updated 28 Dec 2021 |
03 Dec 2021 | Other trial event | Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023. Updated 28 Dec 2021 |
04 Oct 2021 | Results | Results published in the JAMA: the Journal of the American Medical Association Updated 11 Oct 2021 |
02 Oct 2021 | Other trial event | Last checked against University Hospital Medical Information Network - Japan record. Updated 02 Oct 2021 |
30 Sep 2021 | Other trial event | According to Trevena media release, data from this trial is expected in mid 2022 Updated 05 Oct 2021 |
04 Aug 2021 | Results | Results of open-label, adaptive, multiplatform (NCT04372589, NCT04505774. NCT02735707.and NCT04359277) trial assessing therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19, published in the New England Journal of Medicine Updated 13 Aug 2021 |
04 Aug 2021 | Results | Results assessing initial strategy of therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin improves in-hospital survival and reduces the duration of intensive care unit (ICU)level cardiovascular or respiratory organ support in critically ill patients with Covid-19published in the New England Journal of Medicine Updated 13 Aug 2021 |
01 Aug 2021 | Results | Results (n=694) assessing efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019, published in the Intensive Care Medicine. Updated 19 Aug 2021 |
12 Jul 2021 | Other trial event | According to a Global Coalition for Adaptive Research media release, the U.S. Sponsor of REMAP COVID, announced that Amgens apremilast (Otezla) has ended evaluation in the REMAP COVID study Updated 19 Jul 2021 |
21 Jun 2021 | Other trial event | According to a NovaBiotics media release, company's intravenous (IV) cysteamine bitartrate (NM002) therapy candidate has been included in this global Phase 3 clinical trial. Updated 25 Jun 2021 |
21 Apr 2021 | Other trial event | According to a Trevena media release, TRV027 has been selected for inclusion in an international, multi-site, adaptive, trial in COVID-19 patients. David Owen, M.D., Ph.D., the chief investigator of Imperial College London's TRV027 study, has joined the investigator team committee for the REMAP-CAP RAS domain study. Updated 26 Apr 2021 |
25 Feb 2021 | Results | Results assessing effectiveness of tocilizumab and sarilumab on survival and organ support in critically ill patients with Covid-19, published in the New England Journal of Medicine Updated 05 Mar 2021 |
22 Jan 2021 | Other trial event | According to a NYU Grossman School of Medicine media release, Patrick Lawler is a member of the international trial steering committee for this trial. Updated 09 Feb 2021 |
08 Dec 2020 | Other trial event | New source identified and integrated (University Hospital Medical Information Network - Japan: UMIN000042594). Updated 08 Dec 2020 |
01 Dec 2020 | Other trial event | According to University Hospital Medical Information Network - Japan record, the last follow-up date is 31 Dec 2025. Updated 09 Dec 2020 |
27 Oct 2020 | Other trial event | According to an Global Coalition for Adaptive Research (GCAR ) media release, GCAR is serving as USA Trial Sponsor of REMAP-CAP study. Updated 30 Oct 2020 |
27 Oct 2020 | Other trial event | According to an Global Coalition for Adaptive Research media release, the company along with the Amgen and Eisai has enrolled the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP Updated 29 Oct 2020 |
26 Sep 2020 | Other trial event | Planned number of patients changed from 4000 to 6800. Updated 28 Sep 2020 |
02 Sep 2020 | Results | Results (n=384) published in the JAMA: the Journal of the American Medical Association Updated 07 Sep 2020 |
22 Jul 2020 | Other trial event | New source identified and integrated( ISRCTN: Current Controlled Trials: 67000769) Updated 22 Jul 2020 |
01 Jul 2020 | Protocol amendment | According to an Eisai Co media release, when COVID-19 began, the REMAP-CAP study rapidly pivoted to its pandemic mode (the REMAP-COVID substudy), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. Updated 20 Jul 2020 |
01 Jul 2020 | Other trial event | According to an Eisai Co media release, Christopher Seymour, M.D, MSC, Associate Professor, Department of Critical Care Medicine at the University of Pittsburgh and UPMC is a USA principle investigator of the REMAP-CAP:COVID study. Updated 04 Jul 2020 |
01 Jul 2020 | Other trial event | According to an Eisai Co media release, Eritoran has been selected as the first investigational immune modulation therapy to be evaluated in the moderate patient group of REMAP-COVID. This trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites including Japan, will follow. Updated 04 Jul 2020 |
01 Jul 2020 | Other trial event | According to an Eisai Co media release, the Global Coalition for Adaptive Research (GCAR) collaborated with UPMC (University of Pittsburgh Medical Center) and Eisai to join REMAP-COVID, a substudy of REMAP-CAP. Updated 04 Jul 2020 |
17 Jun 2020 | Other trial event | According to results published in the JAMA: the Journal of the American Medical Association, in response to discussions held across the participating sites, the blinded international trial steering committee decided to stop enrollment of patients with COVID-19 in the corticosteroid domain due to a loss of equipoise. No data from the trial were reviewed prior to the decision. Follow-up of the domain was ended August 12,2020. Updated 26 Apr 2021 |
27 Apr 2020 | Other trial event | According to a Faron Pharmaceuticals media release, this trial is underway more than 60 sites and 13 countries (announced on 01 April 2020). Updated 04 May 2020 |
15 Apr 2020 | Other trial event | Planned number of patients changed from 6800 to 7100. Updated 17 Apr 2020 |
15 Apr 2020 | Completion date | Planned End Date changed from 1 Jun 2022 to 1 Dec 2023. Updated 17 Apr 2020 |
01 Apr 2020 | Other trial event | According to a Faron Pharmaceuticals media release, this study is supported by several funding agencies all over the world. Updated 06 Apr 2020 |
16 Aug 2018 | Completion date | Planned End Date changed from 1 Feb 2019 to 1 Jun 2022. Updated 27 Aug 2018 |
16 Aug 2018 | Other trial event | Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2021. Updated 27 Aug 2018 |
03 Aug 2018 | Other trial event | Planned number of patients changed from 4000 to 6800. Updated 08 Aug 2018 |
15 Apr 2016 | Other trial event | New source identified and integrated (ClinicalTrials.gov NCT02735707). Updated 15 Apr 2016 |
09 Oct 2015 | New trial record | New trial record Updated 09 Oct 2015 |
Table of Contents
References
-
Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2022;.
PubMed | CrossRef Fulltext -
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. . JAMA 2021;.
PubMed | CrossRef Fulltext -
Trevena. Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients. Media-Rel 2021;.
Media Release -
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive-Care-Med 2021;47(8):867-886.
PubMed | CrossRef Fulltext -
Trevena. Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients. Media-Rel 2021;.
Media Release -
ISRCTN: Current Controlled Trials. Trial-Reg 2023;.
Available from: URL: http://www.controlled-trials.com -
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. . N-Engl-J-Med 2021;.
PubMed | CrossRef Fulltext -
European Clinical Trials Database. Trial-Reg 2023;.
Available from: URL: https://www.clinicaltrialsregister.eu -
Hills TE, Lorenzi E, Berry LR, Shyamsundar M, Al-Beidh F, Annane D, et al. Simvastatin in Critically Ill Patients with Covid-19. . N-Engl-J-Med 2023;.
PubMed | CrossRef Fulltext -
Global Coalition for Adaptive Research. Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Apremilast in REMAP-COVID. Media-Rel 2021;.
Media Release -
Global Coalition for Adaptive Research. Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial. Media-Rel 2020;.
Media Release -
NovaBiotics. NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia. Media-Rel 2021;.
Media Release -
Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. . N-Engl-J-Med 2021;.
PubMed | CrossRef Fulltext -
University Hospital Medical Information Network - Japan. Trial-Reg 2021;.
Available from: URL: http://www.umin.ac.jp -
Eisai Co Ltd. REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID. Media-Rel 2020;.
Media Release -
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N-Engl-J-Med 2021;.
PubMed | CrossRef Fulltext -
Goligher EC, Lawler PR, Jensen TP, Talisa V, Berry LR, Lorenzi E, et al. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA 2023;.
PubMed | CrossRef Fulltext -
NYU Grossman School of Medicine. Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients in international trial. Media-Rel 2021;.
Media Release -
NovaBiotics. NovaBiotics Announces First Patient Enrollment into the Cysteamine Domain of REMAP-CAP. Media-Rel 2021;.
Media Release -
Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. . JAMA 2023;329(14):1183-1196.
PubMed | CrossRef Fulltext -
Faron Pharmaceuticals. Traumakine to be a part of WHO's Solidarity trial investigating potential COVID-19 treatments. Media-Rel 2020;.
Media Release -
Global Coalition for Adaptive Research. Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID. Media-Rel 2022;.
Media Release -
Faron Pharmaceuticals. REMAP-CAP to study IFN beta-1a effect in COVID-19. Media-Rel 2020;.
Media Release -
Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. . JAMA 2020;.
PubMed | CrossRef Fulltext
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG